EGFR+ Lung Cancer

Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC) who progressed after first-line crizotinib.

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non&ndash;small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.

Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non&ndash;small cell lung cancer (NSCLC) with PD-L1 expression on &ge;50% of cells, according to findings from the phase III KEYNOTE-024 trial.

Benjamin P.&nbsp;Levy, MD, medical director of thoracic medical oncology for Mount Sinai Health Systems and the associate medical director of the cancer clinical trials office for Mount Sinai Hospital, New York,&nbsp;discusses the tools currently available for predicting mortality risk in patients with early stage lung cancer.

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with&nbsp;lung cancer have shown promising results for these combinations.&nbsp;

Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC&nbsp;during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate (ORR) of 20% when administered to patients with advanced c-MET&ndash;dysregulated non&ndash;small cell lung cancer (NSCLC).

In an interview with <em>Targeted Oncology</em>, Naiyer Rizvi, MD, director of Thoracic Oncology and Immunotherapy at Columbia University Medical Center, discusses data from the&nbsp;phase III KEYNOTE-024 trial and expressed his optimism about immunotherapy in the NSCLC field.

According to results from the phase III ASCEND-4 trial, ceritinib (Zykadia) improved progression-free survival (PFS) compared with standard chemotherapy as a first-line treatment for patients with <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC)

Metastatic Lung Cancer with Jared M. Weiss, MD

Metastatic Lung Cancer with Jared M. Weiss, MD

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).

Merck, the manufacturer of pembrolizumab (Keytruda), has announced the FDA has granted priority review to a supplemental biologics license application (sBLA) for the PD-1 inhibitor as a first-line treatment for patients with PD-L1-positive non-small cell lung cancer (NSCLC).

James Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the use of endobronchial ultrasound (EBUS) in the diagnosis of lung cancer.